Compare Coupang Inc (CPNG) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Coupang Inc vs Merck & Co., Inc. — how do they compare? Coupang Inc trades at $15.83 (market cap $27.70B), while Merck & Co., Inc. trades at $146.05 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 12.7× Coupang Inc's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Coupang Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Coupang Inc for 55 Days and Merck & Co., Inc. for 98 Days on average.
| CPNG | MRK | |
|---|---|---|
Market Cap | $27.70B | $351.28B |
Volume | 27,703,608 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $32.47 | $156.43 |
52-Week Low | $13.75 | $82.49 |
Typical Hold Time | 55 Days | 98 Days |
Enterprise Value | $27.22B | $398.04B |
Dividend Yield | — | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Coupang (CPNG) trades at $15.82, up 6.82% today, showing strong momentum despite recent earnings misses. The stock maintains a bullish technical outlook with positive moving averages and institutional support. Revenue growth remains robust at $34.53 billion for 2025, though profitability metrics show challenges with negative net income margin and ROE. Analyst consensus is strongly bullish with 87.5% buy ratings and a $25.25 price target, representing significant upside potential from current levels.
The investment case hinges on Coupang's dominant South Korean market position and expanding logistics network, but faces headwinds from inconsistent profitability and competitive pressures. While valuation appears reasonable on sales (P/S 0.8), high P/E ratio reflects earnings volatility. Key risks include execution challenges in international expansion and margin pressure from logistics investments. The stock offers growth exposure but requires careful monitoring of profitability trends.
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Coupang Inc
Coupang Inc is an e-commerce company. The company sells apparel, electronics, footwear, food products, furniture, nutritional supplements, and other products. Its segments include Product Commerce and Growth Initiatives.
Read more on CPNG →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
